Dr. Dan S. Zuckerman, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 24
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 269
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
ID license M10165
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- St Luke's Regional Medical Center Boise, ID
- St Luke's Nampa Medical Center Nampa, ID
- St Luke's Wood River Medical Center Ketchum, ID
- St Luke's Elmore Medical Center Mountain Home, ID
- St Luke's Mccall Mccall, ID
Medical groups
- St Lukes Clinic-Treasure Valley LLC (1,173 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 269
- Services billed
- 1,112
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 405 | 129 |
| Established patient office or other outpatient visit, 20-29 minutes | 145 | 107 |
| Established patient office or other outpatient visit, 40-54 minutes | 106 | 52 |
| New patient office or other outpatient visit, 45-59 minutes | 28 | 28 |
| New patient office or other outpatient visit, 60-74 minutes | 21 | 21 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prochlorperazine Maleate Other prescribers in Boise, ID | 90 |
| Ondansetron Odt (ondansetron) Other prescribers in Boise, ID | 87 |
| Eliquis (apixaban) Other prescribers in Boise, ID | 44 |
| Prednisone Other prescribers in Boise, ID | 42 |
| Oxycodone Hcl Other prescribers in Boise, ID | 38 |
| Creon (lipase/protease/amylase) Other prescribers in Boise, ID | 35 |
| Dexamethasone Other prescribers in Boise, ID | 32 |
| Lidocaine-Prilocaine (lidocaine/prilocaine) Other prescribers in Boise, ID | 30 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Boise, ID | 26 |
| Revlimid (lenalidomide) | 19 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 4 payments worth $2,053 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $2,010 |
|---|---|
| E.r. Squibb & Sons, L.l.c. | $28.89 |
| Genentech, Inc. | $14.58 |
| Consulting Fee | $2,010 |
|---|---|
| Food and Beverage | $43.47 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Jan 17, 2025 | Consulting Fee | $2,010 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $211,650 in research payments for these studies, mostly to the institutions running them.
- A phase 3 multi center,open label,sponsor blinded,randomized study of azd0901 monotherapy compared with investigator s choice of therapy in second or later line adult participants with advanced metastatic gastric or g…
AstraZeneca Pharmaceuticals LP - CHS38802
Coherus Oncology, Inc. - M24-064 - A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult P…
AbbVie Inc. - A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer
AbbVie Inc. · Active, not recruiting · NCT06614192 - A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT06855771
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.